These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-
...
XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB.
This Rapid Communication is released in advance of updated WHO consolidated guidelines expected later in 2022, to inform national TB programmes and other stakeholders of key changes in the treatment of DR-TB and to allow for rapid transition and planning at the country level.
more
Clinical guidelines for the comprehensive care of patients with drug-resistant tuberculosis
This study consists of a descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015, being the first report of a genotypic testing used to provide information about second line drug resistance in Mozambique.
BMC Infectious Diseases (2016) 16:423 DO
...
I 10.1186/s12879-016-1766-x
more
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
Tuberculosis (TB) is an infectious disease that usually affects the lungs, though it can affect any organ in the body. It can develop when bacteria spread through droplets in the air. TB can be fata
...
l, but in many cases, TB is preventable and treatable. This report examines the human rights impact of the prevalence of Tuberculosis (TB) and Multi-drug-resistant tuberculosis (MDR-TB) among the Indigenous San peoples of Namibia. Combining political economy and root-cause methodology, the report explores the socioeconomic factors that make the San vulnerable to TB and limit their access to adequate health services.
more
Framework for implementation.
The END TB Strategy.
This e-course will guide you through the essentials of latest existing WHO guidelines and policy recommendations on drug-resistant TB. You will als
...
o learn more about the rationale behind the WHO recommendations for the management of DR-TB, implementation considerations for different regimens for eligible patient groups, adjunctive treatment, the active TB drug safety monitoring and management framework, and the analysis and interpretation of performance indicators.
The main focus of the e-course is programmatic; clinical aspects are only discussed when relevant to specific topics.
more
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
Technical information note. Ensuring an uninterrupted supply of quality-assured, affordable anti-TB
drugs and diagnostics to the world
The World Health Organization Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and progress in the response, at global, regional and country levels.
The 202
...
2 edition features data on disease trends and the response to the epidemic from 215 countries and areas, including all 194 World Health Organization (WHO) Member States. It provides a comprehensive and up-to-date assessment of the TB epidemic, progress in the response at global, regional and country levels, as well as on the impact of the COVID-19 pandemic on TB services.
TB remains one of the top infectious killers in the world. This year’s report presents data on an increase in the number of people falling ill with TB and drug resistant TB for the first time in many years. Increases were also reported on the number of TB deaths, highlighting the severe impact of the COVID-19 pandemic and other crises on the TB response that has reversed years of progress. It also presents the status of progress towards targets set at the first-ever United Nations General Assembly high-level meeting on TB in 2018 as well as the targets of the WHO End TB Strategy and the Sustainable Development Goals.
more
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
The consolidated guidelines are complemented by an operational handbook which is designed to assist with implementation of the WHO recommendations by Member States, technical partners and others who are involved in the management of patients with DR-TB
...
. The WHO Operational Handbook on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment provides practical guidance on how to put in place the recommendations at the scale needed to achieve national and global impact.
The operational handbook provides practical information and tools that complement the recommendations in the guidelines. The strategies described in the operational handbook are based on the latest WHO recommendations which were formulated by Guideline Development Groups using the GRADE approach. In many cases however, the recommendations in their current form lacked sufficient clinical and programmatic detail, which is important for implementation. This operational handbook complements the guidelines with practical advice based on best practices and knowledge from the fields such as pharmacokinetics, pharmacodynamics, microbiology, pharmacovigilance and clinical and programmatic management.
more